Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny Inc. has experienced a significant 39% year-over-year increase in egg retrievals and banking, highlighting robust demand for its fertility services, particularly among women in the tech sector. The company is poised to capitalize on expanding revenue opportunities from the implementation of IVF mandates across more states and the launch of its fully-insured product offering, which is expected to provide incremental growth starting in FY27. Furthermore, with nearly 100% client retention and a growing number of covered lives gaining access to ancillary services—projected to rise from 1.5 million in 2025 to 2.7 million in 2026—Progyny showcases a strong business model and market position that supports a positive outlook.

Bears say

The financial outlook for Progyny Inc. is negative due to the potential impact of economic uncertainty and rising unemployment, which may dissuade employees from pursuing family building through the company's fertility benefit offerings. The company's adjusted EBITDA guidance has been lowered to a range of $224 to $239 million, falling short of both prior estimates and consensus expectations, reflecting challenges in revenue growth and market dynamics. Additionally, a decrease in projected covered lives from 7.6 million to 7.2 million signals a loss of client engagement in a competitive landscape, further exacerbating concerns about sustaining operational performance.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.